The inhibition of the AChE enzyme using specific inhibitors has emerged as a promising therapeutic approach for managing a range of neurological disorders including Lewy body dementia and Alzheimer’s disease (AD) [1,2]. This evidence concerns the gene ACHE and Lewy body dementia.